Matches in SemOpenAlex for { <https://semopenalex.org/work/W2911291804> ?p ?o ?g. }
- W2911291804 endingPage "937" @default.
- W2911291804 startingPage "919" @default.
- W2911291804 abstract "Background: Extracellular purines and pyrimidines have important physiological functions in mammals. Purines and pyrimidines act on P1 and P2 purinergic receptors, which are widely expressed in the plasma membrane in various cell types. P2 receptors act as important therapeutic targets and are associated with several disorders, such as pain, neurodegeneration, cancer, inflammation, and thrombosis. However, the use of antagonists for P2 receptors in clinical therapy, with the exception of P2Y12, is a great challenge. Currently, many research groups and pharmaceutical companies are working on the development of specific antagonist molecules for each receptor subtype that could be used as new medicines to treat their respective disorders. Objective: The present review compiles some interesting findings on the application of P2 receptor antagonists in different in vitro and in vivo experimental models as well as the progress of advanced clinical trials with these compounds. Conclusion: Despite all of the exciting results obtained on the bench, few antagonists of P2 receptors advanced to the clinical trials, and once they reach this stage, the effectiveness of the therapy is not guaranteed, as in the example of P2X7 antagonists. Despite this, P2Y12 receptor antagonists have a history of success and have been used in therapy for at least two decades to prevent thrombosis in patients at risk for myocardial infarctions. This breakthrough is the motivation for scientists to develop new drugs with antagonistic activity for the other P2 receptors; thus, in a matter of years, we will have an evolution in the field of purinergic therapy." @default.
- W2911291804 created "2019-02-21" @default.
- W2911291804 creator A5023871149 @default.
- W2911291804 creator A5026250031 @default.
- W2911291804 creator A5090114439 @default.
- W2911291804 date "2019-06-11" @default.
- W2911291804 modified "2023-10-17" @default.
- W2911291804 title "Potential Therapeutic Applications of P2 Receptor Antagonists: From Bench to Clinical Trials" @default.
- W2911291804 cites W144700851 @default.
- W2911291804 cites W1493080707 @default.
- W2911291804 cites W1527325387 @default.
- W2911291804 cites W1536345883 @default.
- W2911291804 cites W1553109446 @default.
- W2911291804 cites W1553345686 @default.
- W2911291804 cites W1571993753 @default.
- W2911291804 cites W1576385546 @default.
- W2911291804 cites W159217275 @default.
- W2911291804 cites W1669284093 @default.
- W2911291804 cites W1791708082 @default.
- W2911291804 cites W1811472601 @default.
- W2911291804 cites W1834826820 @default.
- W2911291804 cites W1918150899 @default.
- W2911291804 cites W196615512 @default.
- W2911291804 cites W1966466072 @default.
- W2911291804 cites W1968586537 @default.
- W2911291804 cites W1968794258 @default.
- W2911291804 cites W1969353966 @default.
- W2911291804 cites W1970597425 @default.
- W2911291804 cites W1974804087 @default.
- W2911291804 cites W1975172757 @default.
- W2911291804 cites W1975655118 @default.
- W2911291804 cites W1976438029 @default.
- W2911291804 cites W1979176284 @default.
- W2911291804 cites W1979314568 @default.
- W2911291804 cites W1980844290 @default.
- W2911291804 cites W1983741516 @default.
- W2911291804 cites W1984025105 @default.
- W2911291804 cites W1985668404 @default.
- W2911291804 cites W1988521658 @default.
- W2911291804 cites W1990818247 @default.
- W2911291804 cites W1991493628 @default.
- W2911291804 cites W1995102677 @default.
- W2911291804 cites W1996543066 @default.
- W2911291804 cites W1999509469 @default.
- W2911291804 cites W2004017460 @default.
- W2911291804 cites W2007204309 @default.
- W2911291804 cites W2014436375 @default.
- W2911291804 cites W2014755783 @default.
- W2911291804 cites W2015130930 @default.
- W2911291804 cites W2015684399 @default.
- W2911291804 cites W2021505088 @default.
- W2911291804 cites W2021847219 @default.
- W2911291804 cites W2022548397 @default.
- W2911291804 cites W2028010252 @default.
- W2911291804 cites W2028222722 @default.
- W2911291804 cites W2028598961 @default.
- W2911291804 cites W2033980540 @default.
- W2911291804 cites W2034866920 @default.
- W2911291804 cites W2035927398 @default.
- W2911291804 cites W2037178734 @default.
- W2911291804 cites W2037226111 @default.
- W2911291804 cites W2039539607 @default.
- W2911291804 cites W2039806177 @default.
- W2911291804 cites W2041055010 @default.
- W2911291804 cites W2041686781 @default.
- W2911291804 cites W2044723926 @default.
- W2911291804 cites W2047429147 @default.
- W2911291804 cites W2052108780 @default.
- W2911291804 cites W2052870901 @default.
- W2911291804 cites W2054313278 @default.
- W2911291804 cites W2054643756 @default.
- W2911291804 cites W2054673562 @default.
- W2911291804 cites W2054924316 @default.
- W2911291804 cites W2059490337 @default.
- W2911291804 cites W2059716980 @default.
- W2911291804 cites W2060636124 @default.
- W2911291804 cites W2068568471 @default.
- W2911291804 cites W2070663123 @default.
- W2911291804 cites W2070801481 @default.
- W2911291804 cites W2071777696 @default.
- W2911291804 cites W2073021418 @default.
- W2911291804 cites W2073451266 @default.
- W2911291804 cites W2074152542 @default.
- W2911291804 cites W2074779058 @default.
- W2911291804 cites W2079369070 @default.
- W2911291804 cites W2085731175 @default.
- W2911291804 cites W2087103870 @default.
- W2911291804 cites W2090346027 @default.
- W2911291804 cites W2094549432 @default.
- W2911291804 cites W2095795382 @default.
- W2911291804 cites W2097677296 @default.
- W2911291804 cites W2098109360 @default.
- W2911291804 cites W2102040360 @default.
- W2911291804 cites W2102694854 @default.
- W2911291804 cites W2104485689 @default.
- W2911291804 cites W2108602500 @default.
- W2911291804 cites W2110861336 @default.
- W2911291804 cites W2119767998 @default.